Breast Device Surgery in Australia: Early Results from the Australian Breast Device Registry.


Journal

Journal of plastic, reconstructive & aesthetic surgery : JPRAS
ISSN: 1878-0539
Titre abrégé: J Plast Reconstr Aesthet Surg
Pays: Netherlands
ID NLM: 101264239

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 04 05 2020
revised: 03 03 2021
accepted: 13 03 2021
pubmed: 2 5 2021
medline: 16 11 2021
entrez: 1 5 2021
Statut: ppublish

Résumé

The Australian Breast Device Registry (ABDR) is a clinical quality registry designed to monitor the performance of breast devices; and the quality and safety of breast device surgery. To report on breast device surgery characteristics across Australia. Participants were registered patients in the ABDR from 2012 to 2018. Results are described using percentages, mean and median. Revision rates were calculated using survival analysis methods. A total of 37,603 patients were registered and had undergone reconstruction (post-cancer 15.1%, risk-reducing mastectomy 3.4% and developmental deformity 2.4%) or cosmetic augmentation (74.7%) procedures. The majority of breast implant devices were silicone filled with textured surface (reconstruction 74.0% and augmentation 64.0%). Sub-pectoral plane was the most common for both reconstruction (60.1%) and augmentation (76.6%) procedures. For reconstruction surgery, the most common surgical incision was previous mastectomy scar (44.0%) and inframammary (31.8%), and for augmentation, it was inframammary (83.4%). Intraoperative/postoperative antibiotic usage for reconstruction was 85.8% and augmentation was 89.4%. Revision incidence due to complication at 12 months post-cancer reconstruction was 5.1%, risk-reducing reconstruction 5.7% and developmental deformity implants 4.5%. Revision incidence due to complication at 12 months after augmentation procedure was 1.1%. Patient-reported outcome measures (PROMs) indicate high levels of satisfaction at 1 year for augmentation and reconstruction procedures. We report on early data from the ABDR and reflect on the uptake of the registry by surgeons and patients. The registry also benefits from international collaborative approaches to addressing challenges and is committed to facilitate international post-market surveillance.

Sections du résumé

BACKGROUND BACKGROUND
The Australian Breast Device Registry (ABDR) is a clinical quality registry designed to monitor the performance of breast devices; and the quality and safety of breast device surgery.
OBJECTIVE OBJECTIVE
To report on breast device surgery characteristics across Australia.
METHODS METHODS
Participants were registered patients in the ABDR from 2012 to 2018. Results are described using percentages, mean and median. Revision rates were calculated using survival analysis methods.
RESULTS RESULTS
A total of 37,603 patients were registered and had undergone reconstruction (post-cancer 15.1%, risk-reducing mastectomy 3.4% and developmental deformity 2.4%) or cosmetic augmentation (74.7%) procedures. The majority of breast implant devices were silicone filled with textured surface (reconstruction 74.0% and augmentation 64.0%). Sub-pectoral plane was the most common for both reconstruction (60.1%) and augmentation (76.6%) procedures. For reconstruction surgery, the most common surgical incision was previous mastectomy scar (44.0%) and inframammary (31.8%), and for augmentation, it was inframammary (83.4%). Intraoperative/postoperative antibiotic usage for reconstruction was 85.8% and augmentation was 89.4%. Revision incidence due to complication at 12 months post-cancer reconstruction was 5.1%, risk-reducing reconstruction 5.7% and developmental deformity implants 4.5%. Revision incidence due to complication at 12 months after augmentation procedure was 1.1%. Patient-reported outcome measures (PROMs) indicate high levels of satisfaction at 1 year for augmentation and reconstruction procedures.
CONCLUSION CONCLUSIONS
We report on early data from the ABDR and reflect on the uptake of the registry by surgeons and patients. The registry also benefits from international collaborative approaches to addressing challenges and is committed to facilitate international post-market surveillance.

Identifiants

pubmed: 33931327
pii: S1748-6815(21)00125-X
doi: 10.1016/j.bjps.2021.03.035
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Silicone Gels 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2719-2730

Informations de copyright

Copyright © 2021 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Swarna Vishwanath (S)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Breanna Pellegrini (B)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Emily Parker (E)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Arul Earnest (A)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Saeid Kalbasi (S)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Pragya Gartoulla (P)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Elisabeth Elder (E)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Westmead Breast Cancer Institute, Australia; University of Sydney, Sydney, Australia; Breast Surgeons of Australia & New Zealand, Australia.

Gillian Farrell (G)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Cabrini Hospital - Brighton, Australia; Peter McCallum Cancer Centre, Melbourne, Australia; Australian Society of Plastic Surgeons, Australia.

Colin Moore (C)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Australasian College of Cosmetic Surgery, Australia.

Rodney D Cooter (RD)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Susannah Ahern (S)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

John J McNeil (JJ)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Ingrid Hopper (I)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Electronic address: Ingrid.hopper@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH